UK markets close in 2 hours 53 minutes

Vifor Pharma AG (GNHAY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
28.430.00 (0.00%)
At close: 9:33AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close28.43
BidN/A x N/A
AskN/A x N/A
Day's range28.43 - 28.43
52-week range25.81 - 32.10
Avg. volume44
Market cap9.219B
Beta (5Y monthly)1.32
PE ratio (TTM)20.52
Earnings dateN/A
Forward dividend & yield0.44 (1.55%)
Ex-dividend date10 May 2021
1y target estN/A
  • Motley Fool

    Why Cara Therapeutics Shot Higher Today

    Cara Therapeutics (NASDAQ: CARA) was a hot stock on Tuesday. One of the formerly clinical-stage biotech's drug candidates won FDA approval, and investors reacted in the usual manner. The biotech company's most promising drug, Korsuva --- developed with Switzerland-based Vifor Pharma -- addresses this medical challenge sufficiently to win that all-important FDA approval.

  • Zacks

    CARA Drug Wins FDA Nod for Pruritus Associated With CKD

    CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.

  • Motley Fool

    Cara Therapeutics, inc (CARA) Q2 2021 Earnings Call Transcript

    This is Cole Herlitz-Ferguson with Stern Investor Relations and welcome to Cara Therapeutics' second quarter 2021 financial results and update conference call. Before we begin, let me remind you that statements made on today's call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.